Novavax to Create an Omicron-Specific Vaccine, While Assessing Current Jab’s Effect On the Variant

Novavax is throwing two punches at Omicron, the new COVID-19 variant that’s sparking fresh waves of travel restrictions: evaluating how well its lead COVID-19 vaccine candidate NVX-CoV2373 targets the new variant and creating a new vaccine made specifically to target the highly mutated virus.
Source: Drug Industry Daily